Abbvie Inc [NYSE: ABBV] price surged by 0.92 percent to reach at $1.61. The company report on February 22, 2024 at 8:05 AM that AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology.
Collaboration to leverage AbbVie’s therapeutic area expertise and Tentarix’s Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix.
The one-year ABBV stock forecast points to a potential upside of 0.84. The average equity rating for ABBV stock is currently 1.89, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Abbvie Inc [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $178.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 1.89. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Abbvie Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 29, 2024. The new note on the price target was released on December 18, 2023, representing the official price target for Abbvie Inc stock.
The Average True Range (ATR) for Abbvie Inc is set at 2.99, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 5.75. The Price to Book ratio for the last quarter was 30.13, with the Price to Cash per share for the same quarter was set at 7.26. Price to Free Cash Flow for ABBV in the course of the last twelve months was 14.18 with Quick ratio for the last quarter at 0.76.
ABBV Stock Performance Analysis:
Abbvie Inc [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.34. With this latest performance, ABBV shares gained by 5.52% in over the last four-week period, additionally plugging by 19.23% over the last 6 months – not to mention a rise of 16.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 70.47, with the RSI for the last a single of trading hit 69.53, and the three-weeks RSI is set at 70.48 for Abbvie Inc [ABBV]. The present Moving Average for the last 50 days of trading for this stock 163.81, while it was recorded at 176.34 for the last single week of trading, and 148.82 for the last 200 days.
Insight into Abbvie Inc Fundamentals:
Abbvie Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.76 and a Current Ratio set at 0.87.
ABBV Stock EPS
With the latest financial reports released by the company, Abbvie Inc posted 2.46/share EPS, while the average EPS was predicted by analysts to be reported at 2.46/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbvie Inc go to 3.28%.
Abbvie Inc [ABBV] Institutonal Ownership Details
The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ABBV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ABBV stock with ownership which is approximately 5.8325%.
